secwatch.observer — SEC 8-K summary
======================================

Issuer:     TCR2 THERAPEUTICS INC. (—)
CIK:        0001750019
Form:       8-K
Filed at:   2023-01-05T23:59:59+00:00
Accession:  0001193125-23-002029
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 2.05, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TCR2 Therapeutics cuts workforce ~40%, prioritizes gavo-cel ovarian cancer & second-gen programs
--------------------------------------------------------------------------------

- Workforce reduced ~40%; $3M pre-tax severance/termination charges expected in Q1 2023.
- gavo-cel Phase 2 now focused solely on ovarian cancer cohort; durability data expected 2H 2023.
- Second-gen TC-510 (PD-1:CD28 switch) Phase 1 ongoing; objective response data expected 2H 2023.
- Cash runway extended into early 2025 due to cost savings from restructuring.
- TC-520 (anti-CD70 with IL-15 enhancements) advancing to IND.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750019/000119312523002029/0001193125-23-002029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750019/000119312523002029/d438413d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-002029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer